Olmesartan/amlodipine/hydrochlorothiazide single-pill combination therapy resulted in a 4.44% incidence of hypotension-related adverse events in elderly patients, showing no significant excess risk compared to non-elderly patients (RR 0.79).
Observational (n=10,948)
Sí
Does olmesartan/amlodipine/hydrochlorothiazide single-pill combination therapy safely reduce blood pressure without increasing hypotension-related adverse events in older and very elderly patients?
Olmesartan/amlodipine/hydrochlorothiazide single-pill combination therapy effectively lowers blood pressure in older and very elderly patients without increasing the risk of hypotension-related adverse events compared to younger patients.
Estimación del efecto: RR 0.79 (95% CI 0.62-1.00)
Tasa de eventos absoluta: 4.44% vs 4.82%
Clinical Research Information Service-Republic of Korea, KCT0010343 (https: //cris. nih. go. kr/cris/search/detailSearch. do? seq=29557&searchₚage=L).
“This RESOLVE-PRO study is a prospective study conducted in an actual medical environment in Korea. The study provided valuable data as we could confirm the strong antihypertensive effect and safety of an olmesartan-based triple-combination drug in high-risk hypertensive patients over a year.”
Kim et al. (Tue,) conducted a observational in Hypertension (n=10,948). Olmesartan/Amlodipine/Hydrochlorothiazide (O/A/H) single-pill combination vs. Non-elderly patients (< 65 years) was evaluated on Incidence of hypotension-related adverse events (composite of hypotension, dizziness, syncope, falls/fractures) (RR 0.79, 95% CI 0.62-1.00). Olmesartan/amlodipine/hydrochlorothiazide single-pill combination therapy resulted in a 4.44% incidence of hypotension-related adverse events in elderly patients, showing no significant excess risk compared to non-elderly patients (RR 0.79).